ERBB2 and breast cancer: Black women aged 50 or older at diagnosis had an over 50% greater risk of breast cancer-specific mortality for stage IV HR+/HER2− and stage III-IV HER+/HER2+ breast cancer but did not have meaningful differences in risks for TN and HR−/HER2+ disease, compared to non-Hispanic White women of the same age group.